Printer Friendly
The Free Library
14,651,959 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Corporate Profile for GeneMedicine Inc., dated June 28, 1996.


--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and information services See Information Systems. .

These include Dow Jones Dow Jones

the best known of several U.S. indexes of movements in price on Wall Street. [Am. Hist.: Payton, 202]

See : Finance
 News/Retrieval, Bloomberg Financial Markets, Reuter Company Newsyear, Reuter Business Briefing, DataTimes, Nexis, Dialog, NewsNet, America OnLine See AOL. , CompuServe, Delphi, Individual's HeadsUp and First!, Desktop Data's NewsEdge, UMI UMI University Microfilms International
UMI United States Minor Outlying Islands (ISO Country code)
UMI University of Miami
UMI Universal Management Infrastructure (IBM) 
 Data Courier, NewsBank, Information Access Company, Prodigy, Comtex, and many others. -0-

Published Date:   June 28, 1996


Company Name:     GeneMedicine Inc.


Address:          8301 New Trails Drive
                  The Woodlands, Texas 77381


Main Telephone
 Number:          713/364-1150


Chief Executive
 Officer:         Eric Tomlinson, D.Sc., Ph.D.


Investor Relations
& Public Relations
 Contact:         Angela S. Goodwin
 Business number: 713/362-2650
 Home number:     713/807-9015
 e-mail address:  goodwa@gmiatt.attmail.com


URL Address:      www.gmed.com


Trading Symbol:   Nasdaq:GMED


Industry:         Gene Therapy, Biotechnology, Pharmaceuticals


-0-

Company description: As rapid advances in genomic science are increasing the prospects of using beneficial genes for therapeutic purposes, scientists at GeneMedicine are focused on the discovery and development of a broad-based non-viral technology that enables genes to be used in conventional medicine.

The company's "gene medicines" are designed for direct administration to patients to cause the production and distribution of therapeutic proteins within the body. Gene medicines are for acute or chronic use and may be administered through convenient and conventional routes, including intramuscular injection Noun 1. intramuscular injection - an injection into a muscle
injection, shot - the act of putting a liquid into the body by means of a syringe; "the nurse gave him a flu shot"
, inhalation or intravenous injection Noun 1. intravenous injection - an injection into a vein
fix - something craved, especially an intravenous injection of a narcotic drug; "she needed a fix of chocolate"
.

The company's initial business focus is the development of gene medicines for the fields of cancer, pulmonary disease, musculoskeletal disorders and gene vaccines for infectious disease Infectious disease

A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions.
.

GeneMedicine is developing its products through corporate alliances with major biotechnology and pharmaceutical companies. The company has corporate partnerships with Roche Bioscience in the areas of asthma, arthritis and transplant rejection transplant rejection Graft rejection, organ rejection, tissue rejection Immunology The constellation of host immune responses evoked when an allograft tissue is transplanted into a recipient; rejection phenomena may be minimized by optimal matching of MHC antigens  and with Boehringer Mannheim for the development of gene medicines to treat head and neck cancers and melanoma.

The company's current cash position and contractual commitments of capital ensure adequate funding for its planned operations through mid-1999.

CONTACT: GeneMedicine Inc.
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 28, 1996
Words:333
Previous Article:Corporate Profile for NeXstar Pharmaceuticals, dated 6/28/96.
Next Article:FEATURE/Grass that once fed buffalo may feed coal-fired burners; MGE tests prairie grass as fuel.
Topics:



Related Articles
GeneMedicine establishes clinical trial agreement and broad-based research collaboration with Vanderbilt University to develop pulmonary gene...
GeneMedicine Inc. announces third quarter 1994 financial results.
GENEMEDICINE grants Corange $2.1 million exclusive option for cancer alliance.
GeneMedicine adopts Preferred Share Purchase Rights Plan.
Corange makes an additional $4 million equity investment in GeneMedicine.
George B. Thornton will leave GeneMedicine at end of January; GeneMedicine to recruit chief scientific officer.
GeneMedicine Inc. announces first quarter 1996 financial results.
GeneMedicine announces second quarter 1996 financial results.
GeneMedicine Inc. announces appointment of Alain P. Rolland, Ph.D., as vice president, Gene Delivery Sciences to lead its expanded efforts in...
GENEMEDICINE, INC. Commences IL-2 Cancer Gene Medicine Phase I Clinical Trial.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles